Chardan raised the firm’s price target on Krystal Biotech (KRYS) to $212 from $208 and keeps a Buy rating on the shares post the Q3 report. The firm says the Vyjuvek launch remains strong.
Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
The Fly
Krystal Biotech price target raised to $212 from $208 at Chardan
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App